### **Overview** Bliss GVS Pharma Limited (BGPL), established in **1984**, is a globally recognized Indian pharmaceutical company specializing in **suppositories and pessaries**. With over **four decades of expertise**, the company has emerged as a **world leader in specialized dosage forms**, offering more than **400 branded formulations** across **60+ therapeutic segments** in over **60 countries**. Bliss GVS is known for its **innovation, quality, and affordability**, with a strong focus on **emerging markets**, particularly **Sub-Saharan Africa**, and strategic expansion into **regulated markets** such as the **U.S., UK, Canada, Russia, and the EU**. --- ### **Core Business & Product Focus** - **Specialized Dosage Forms:** The company's foundation lies in **suppositories and pessaries**, where it holds a **global leadership position**. It pioneered key advancements in the formulation of **Artesunate suppositories** and was the first Indian company to receive **EU-GMP certification** for suppository manufacturing. - **Therapeutic Expertise:** Products target multiple conditions including: - **Anti-malarial:** Brands like *Gsunate* and *Lonart DS* (WHO-endorsed) are vital in malaria-endemic African regions. - **Anti-haemorrhoidal:** Dual-molecule formulations designed for **geriatric patients** with efficacy in treating piles. - **Anti-inflammatory, antifungal (e.g., *Funbact*), antibacterial, laxative, contraceptive, and analgesic** therapies. - Expanding into **dermatology and herbal medicine** to meet evolving global needs. - **Pipeline & Innovation:** The R&D team, certified by **DSIR (Govt. of India)**, develops **differentiated, commercially viable generics**, biosimilars, and vaccines. The company is investing steadily in **technology transfer, formulation development, and novel delivery systems**. --- ### **Global Presence & Market Strategy** - **Geographic Reach:** Presence in **over 64 countries**, with **Sub-Saharan Africa** historically contributing **over 80% of sales volume**. Key markets include: - **Africa:** Dominant in anti-malarial, dermatology, and gynecology segments. - **India:** Accounts for ~21% of revenue. - **North America & Europe:** Strategic focus on **generic drug supply**, serving **40% of U.S. generic market share** and **25% of UK market**. - **CIS/Russia:** Enabled via **Russian GMP approval** (2022), opening access to the **14th-largest pharmaceutical market by volume**, where over 70% of medicines are imported. - **Expansion Plans:** Actively entering new markets: - **North America (U.S. & Canada)**: Entered through partnerships and direct supply. - **Southeast Asia:** Offices in **Myanmar, Philippines, Vietnam**; direct product registrations underway. - **Europe & Latin America:** Targets include the **Netherlands, Portugal, Latvia, Australia, and CIS nations**. - **Regulatory Strengths:** - Facilities comply with **US FDA, EU-GMP, WHO-GMP, PIC/S, ISO 14001, and OHSAS 18001/45001** standards. - Achieved **EU-GMP certification** for two plants in **Aliyali and Vevoor** (2025). - **USFDA approval** secured in **April 2025** for **Mesalamine Suppositories 1000 mg**, developed with U.S. partner **Rising Pharma Holdings**, targeting a **$29 million U.S. market**. --- ### **Manufacturing & Infrastructure** - **Network:** Operates **eight state-of-the-art manufacturing units** across **Maharashtra** (Palghar, Ambernath, Vevoor) and previously in **Nigeria**. - **Palghar (Maharashtra):** - Capacity: 450M tablets, **580M suppositories & pessaries**, 62M sachets, 30M dry syrups annually. - **Vevoor (Maharashtra):** - Multi-product facility with phase-wise commissioning; **Phase I (2020)** added ~420M units. - New **semi-solid plant (Nov 2024)** boosts capacity in **creams, ointments, gels**. - Annual capacity: 230M tablets, 180M capsules, 67M sachets. - **Nigeria (historical):** Former unit supported local access but operations restructured. - **Future Expansion:** - Investment of **₹30 crore** planned to expand Palghar and Vevoor facilities. - Target: **Commercial operations by FY26 (end of 2026)**. - **Land acquisition (28 acres in Halol, Gujarat)** under SARFAESI Act suggests long-term **infrastructure scaling plans**. --- ### **Sustainability & Operational Resilience** - **Renewable Energy:** - Installed **solar power capacity** totaling **7 MW** across facilities: - **4.5 MW (2022)** → 60–70% of energy needs - Added **3 MW (FY25)** and **2.5 MW (Q4 FY25)** - Reduces **carbon footprint, energy costs**, and enhances energy security. - **Green Manufacturing:** - Captive solar meets **30% at Vevoor** and up to **70% at other sites**. - Aligns with global ESG standards and supports export competitiveness via cost efficiency. --- ### **Research & Development (R&D)** - **Mumbai-based R&D Center:** - DSIR-recognized, **GLP-compliant**, equipped with advanced analytical tools (HPLC, GC, dissolution testers, stability chambers). - Staff of **77+ R&D professionals**, including 30+ core scientists. - Focus: **Formulation development, tech transfer, commercialization, novel dosage forms**. - **Innovation Outcomes:** - Successful development of **FDA-approved Mesalamine Suppositories**. - Pioneered **6-dose Artemether-Lumefantrine (Lonart DS)** and **Dihydroartemisinin-Piperaquine formulations (P-Alaxin)**. - Strong pipeline in **gynecology, urology, anti-infectives, and dermatology**. --- ### **Subsidiaries & Corporate Structure** - **Consolidated Subsidiaries (as of Jul 2025):** 1. **Bliss GVS International Pte. Ltd.** (Singapore) 2. **Kremoint Pharma Private Limited** (India) 3. **Asterisk Lifesciences** (India) - **Step-Down Subsidiary:** - **Eipii Exports Pvt. Ltd.** (70% owned by Kremoint Pharma) - **Asterisk Lifesciences DRC (Democratic Republic of Congo):** Control lost on **February 19, 2024**, indicating strategic **divestment or restructuring** in DRC operations. --- ### **Key Strategic Developments (2024–2025)** | Milestone | Date | Impact | |--------|------|--------| | **USFDA approval for Mesalamine Suppositories** (ANDA via Rising Pharma) | Apr 2025 | Entry into high-value U.S. market; validates R&D strength | | **EU-GMP certification for Aliyali & Vevoor plants** | Jul 2025 | Global market access and credibility | | **Commissioning of semi-solid dosage plant (Vevoor)** | Nov 2024 | Enhances dermatology and topical product output | | **3 MW solar expansion (FY25)** | Jul 2025 | Cost savings, sustainability leadership | | **Leadership in anti-malarial segment** | Ongoing | *Lonart DS* and *Gsunate* are trusted brands in Africa | | **Ghana subsidiary turnaround** | May 2025 | Strengthened brand protection via legal victory; boosts regional stability | --- ### **Leadership & Governance** - **Managing Director:** Instrumental in securing **USFDA and EU-GMP approvals** for breakthrough malaria drugs, driving international expansion, and winning key legal cases (e.g., **Ghana brand protection**). - **Executive Director (Mr. Gagan Harsh Sharma):** Led **Palghar plant expansion**, regulatory approvals, and global market positioning. Their leadership has been pivotal in transforming Bliss GVS into a **global pharmaceutical player** with strong **regulatory, manufacturing, and commercial capabilities**. --- ### **Market & Industry Context** - **India’s Role:** Third-largest global pharmaceutical producer by volume; supplies **20% of global generics**. - **Policy Support:** Government **PLI and SPI schemes** incentivize domestic manufacturing and exports. - **Export Incentive:** **RoDTEP scheme** helps offset export costs, improving international competitiveness.